CAMBRIDGE, Mass., April 15, 2008 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that preclinical data from a model of small cell lung cancer (SCLC) show that following treatment with chemotherapy, once-daily oral administration of IPI-926 leads to a statistically significant delay in tumor re-growth, compared to vehicle control (p=0.01). These results suggest that inhibiting the Hedgehog pathway with IPI-926, Infinity's novel, potent Hedgehog pathway antagonist following chemotherapy delays tumor recurrence in SCLC. These data were presented today during the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California.
